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Abstract
OBJECTIVE: To investigate the effect of thorascop-
ic administration of ginseng polysaccharides (GPS)
plus dendritic cells (DC) on T helper cell type 1/T
helper cell type 2 (Th1/Th2) balance in patients
with non-small cell lung cancer (NSCLC).
METHODS: A total of 96 NSCLC patients were divid-
ed evenly into two groups. The control group was
treated with DCs alone and the treatment group
was treated with DCs plus GPS. After DCs and GPS
were administered thoracoscopically, once a week,
4 times for 30 days, the patients' quality of life was
measured with the Functional Assessment of Can-
cer Treatment-Lung (FACT-L) questionnaire before
and after treatment. Serum interferon-γ (INF-γ), in-
terleukin-4 (IL-4), IL-2 and IL-5 were examined be-
fore and after treatments.
RESULTS: The level of Th1 cytokines (INF-γ, IL-2)
and the ratio of Th1/Th2 cytokines (INF-γ/IL-4, IL-2/
IL-5) increased in both treatment groups, while Th2
cytokines (IL-4, IL-5) and FACT-L scores decreased
(P<0.01). Furthermore, after treatment Th1 cyto-
kines (INF-γ, IL-2) and the ratio of Th1/Th2 cyto-
kines (INF-γ/IL-4, IL-2/IL-5) were higher in the DCs +
GPS group than in the control group (P<0.05). Con-
versely, FACT-L scores and Th2 cytokines (IL-4, IL-5)
were higher in the control group than in the DCs +
GPS group (P<0.05).
CONCLUSION: The treatment regime of DCs plus
GPS had a greater effect on NSCLC patients' im-
mune function as compared with DCs alone. This
was evident by increased expression of Th1 cyto-
kines (INF-γ, IL-2) and the ratio of Th1/Th2 (INF-γ/
IL-4, IL-2/IL-5), as well as by decreased FACT-L
scores and the expression of Th2 cytokines (IL-4,
IL-5).
© 2014 JTCM. All rights reserved.
Key words: Panax; Dendritic cells; Carcinoma,
non-small-cell lung; Interferons; Interleukins
INTRODUCTION
Non-small cell lung carcinoma (NSCLC) is one of the
most malignant tumors and has the highest mortality
rate in China. In addition to traditional treatments in-
cluding surgery, radiotherapy, chemotherapy and mo-
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lecular targeted therapy, recently immunotherapy has
gradually been gaining attention as a treatment op-
tion.1 Dendritic cells (DCs), widely known for their
role as antigen presenting cells (APCs),2 also have an-
ti-tumor functions achieved by regulating immune
function. Previous studies have focused on the subcuta-
neous, venous and lymphatic administration of DCs.3
However, thoracoscopy was shown to be the optimal
method for administration.4
Ginseng polysaccharides (GPS) have been shown to
regulate the immune function of DCs in NSCLC pa-
tients.5 However, no studies on the effect of GPS plus
DCs administered thoracoscopically have been per-
formed. Therefore, the present study was conducted in
NSCLC patients examining the Functional Assessment
of Cancer Treatment-Lung (FACT-L) scores, Th1 cy-
tokines (INF-γ, IL-2) and the ratio of Th1/Th2 cyto-
kines (INF-γ/IL-4,IL-2/IL-5)6,7 in BenQ hospital of
Nanjing.
MATERIALS ANDMETHODS
Patients
A total of 96 patients diagnosed with NSCLC were re-
cruited between January 2010 and July 2013 from
BenQ hospital and randomly divided into two groups
according to random number table: the control group
and treatment group, with 48 patients per group. All
patients were informed and the written informed con-
sent forms were obtained. The study was approved by
the ethics committee of BenQ hospital of Nanjing.
The baseline characteristics between the two groups
were not statistically significant (P>0.05, Table 1).
Diagnostic criteria
Diagnosis of NSCLC was performed following the
World Health Organization lung and pleura tumor his-
tologic classification criteria revised in 20048 and ac-
cording to the International Union of Cancer (UICC)
and the American Association of Cancer (AJCC) diag-
nostic criteria.9
Inclusion criteria
The inclusion criteria for the study were (a) meeting
the diagnosis criteria for NSCLC, according to tumor
staging international standards (TNM) for stage ⅢA
and ⅢB, pathological classification for adenocarcino-
ma, nodular type; (b) having undergone first surgery
and three to six cycles of chemotherapy regimens for
NP, GP or EP; (c) cessation of chemotherapy for be-
tween 1 and 2 months prior to commencement of the
study; (d) aged between 30 and 70 years old; (e) Kar-
nofsky Performance Status (KPS) scores greater than
60 points; (f) signing informed consent form.
Exclusion criteria
The exclusion criteria for the study were (a) postopera-
tive distant metastasis; (b) severe conditions of heart,
cerebrovascular, liver, kidney or hematopoietic sys-
tems; (c) congenital disease or mental illness; (d) preg-
nancy or lactation.
Treatment
All cases were taken the foundation treatment such as
postoperative symptomatic, supportive and targeted
(erlotinib hydrochloride tablet, 150 mg/d, po.) reme-
dy, there was no difference between the foundation
treatment schemes adopted in each group (P>0.05).
On the basis of the treatment, the control group was
treated with DCs alone and the treatment group with
GPS plus DC under the thoracoscope.
Induction and self antigen load of DCs in peripheral
blood: according to the reference,10 collect the whole
Baseline
Age (years)
Sex (n)
TNM stages
Chemotherapy times prior to research
Once chemotherapy regimens
Months after chemotherapy was stopped prior to
research
Range
Mean±standard deviation
Male
Female
Ⅲ A
Ⅲ B
NP
GP
EP
Control group
32-65
51.4±12.3
32
16
36
12
4.1±1.4
40
6
2
1.2±0.3
Treatment group
33-66
54.5±13.2
31
17
34
14
3.9±1.4
39
6
3
1.3±0.3
P value
>0.05
-
>0.05
-
>0.05
-
>0.05
>0.05
-
-
>0.05
Table 1 Baseline clinical characteristics between patient groups (n=48, xˉ ±s)
Notes: control group was treated with DCs only; teatment group was treated with GPS plus DC. NP: vinorelbine and cisplatin; GP: gem-
citabine and cisplatin; EP: etoposide and cisplatin; TNM: tumor staging international standards; GPS: ginseng polysaccharides; DC: den-
dritic cells.
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blood of patients with anticoagulant 100 ml, and col-
lect 2 h-post wall composition of PBMNC (Peripheral
Blood Mononuclear Cell) as precursor cells, With 2 ×
106/mL concentration to join serum-free medium
AIM-V with gm-csf 1000 U/mL, IL-4 1000 U/mL.
To cultivate at the environment of 37℃ , 5%CO2, re-
place half quantity of culture liquid every 3 day. Cul-
tured cells 5 days, add stimulus with tumor antigen 0.5
mL, At the same time to collect the patient's own tu-
mor tissue in 5 days, join the TNF-α (tumor nectosis
factor-alphagene) 20 ng/mL in the seventh day, DCs
with tumor antigen was acquired in the eighth day. On
this basis, To prepare for the next stage of treatment,
the number, survival rate, sterile, gram staining, endo-
toxin, mycoplasma, purity and uniformity of cell quali-
ty of DCs were detected.
Injection of DC or GPS add DC under the thoraco-
scope: the Storz type 260 thoracoscope (Karl Storz
GmbH & Co., Tuttlingen, Germany) and the Stryker
imaging system (Stryker, Kalamazoo, MI, USA) were
used for thoracoscopic administration of DCs and
GPS. DC cells number is 0.06×106/kg, GPS is 0.5 mg/
kg, once a week, 4 times for 30 days. GPS injection
was bought from Shanxi Pude pharmaceutical Co.,
Ltd., Shanxi, China; DCs was obtained from labola-
tory of Jiangsu shuyang hospital of TCM, Jiangsu,
china. Indwelling 1 tube in chest drainage after the
first injection, and arranged another injection with
thoracoscope, strict control of infection, and strength-
en the nursing of chest indwelling catheter for the
prevention and treatment of pleural adhesion in the
course of treatment,and given the extubation after
treatment.
Data collection
Before and after treatment, the FACT-L scores were
measured at dawn and 3 ml of venous blood collected in
the morning, centrifuged force at 2220 × g for 10 min,
and stored at ﹣ 75℃ . After clotting, serum INF-γ,
IL-4, IL-2, IL-5 levels were determined with double
sandwich ELISA (enzyme-linked immuno sorbent as-
say) kits according to the manufacturer's instructions
(Beijing Sizhengbai Biological Technology Co., Ltd.,
Beijing, China). ELISA plates were read on a Rainbow
type spectrophotometer (Tecan Group Ltd.,
Mannedorf, Switzerland).
Statistical methods
Data are presented as the mean ± standard deviation
(SD). The means of the two groups were compared us-
ing a t test. Statistical analysis was performed using
SPSS version 19.0 (IBM Co., Ltd., Armonk, New
York, USA).
RESULTS
FACT-L scores before and after treatment
The mean FACT-L score of each group decreased sig-
nificantly after treatment (P<0.01). Furthermore, after
treatment the mean FACT-L score in the control
group was higher than that in the DC+GPS group (P<
0.05, Table 2).
Expression of Th1 and Th2 cytokines in sera before
and after treatment
The expression of Th1 cytokines (INF-γ, IL-2) and
the ratio of Th1/Th2 cytokines (INF-γ/IL-4,IL-2/
IL-5) increased in each group with treatment, while
Th2 cytokines (IL-4, IL-5) decreased significantly (P<
0.01). Additionally, after treatment Th1 cytokines
(INF-γ, IL-2) and the ratio of Th1/Th2 cytokines
(INF-γ/IL-4, IL-2/IL-5) were greater in the DC+GPS
treatment group than in the control group, while con-
versely Th2 cytokines (IL-4, IL-5) were higher in the
control group than in the DCs + GPS treatment group
(P<0.05, Table 3).
DISCUSSION
Our study revealed that the FACT-L score in patients
decreased after both interventions, and that the effect
of GPS plus DCs was greater than that of DCs alone.
This suggests that GPS interact with DCs to stimulate
the immune system and that the secretion of cytokines
is involved in the regulation of the immune response
to NSCLC. Th1 and Th2 are the two major subtypes
of CD4+ T lymphocytes. Th1 is linked to cell-mediat-
ed immunity and Th1 cells produce INF-γ and IL-2
and inhibit tumor cell proliferation. Th2 mediates the
humoral immune can produce IL-4 , IL-5, and the oth-
er cytokines. In contrast to the Th1 response, the Th2
response can actually promote tumor cell prolifera-
Notes: control group was treated with DCs alone; the treatment group was treated with GPS plus DCs. GPS: ginseng polysaccharides;
DC: dendritic cells; FACT-L: functional assessment of cancer treatment-lung. Compared with the indexes before treatment in each group,
aP<0.01; compared with the indexes after treatment in control group, bP<0.05.
Group
Control
Treatment
Before
After
Before
After
Physical status
22±4
17±4a
23±5
14±3ab
Community/
family status
25±7
18±5a
24±6
1 5±3ab
Emotional
status
17±5
13±4a
19±6
11±3ab
Functional
status
20±5
15±4a
19±6
13±3ab
Additional
status
16±5
12±4a
18±6
10±3ab
Total
99±22
77±15a
98±22
65±16ab
Table 2 FACT-L scores in the two patient groups before and after treatment (scores, n=48, xˉ ±s)
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tion.11 Th1/Th2 cells are in a state of relative balance
under normal circumstances. However, owing to ab-
normal immune function in patients with tumors, the
dynamic balance of Th1/Th2 cytokines is altered,
mainly with decreased function of Th1 and increased
function of Th2 cells.12
The DC has been the focus point of the field of biolog-
ical tumor treatment in recent years.13,14 DC treatment
aims to regulate the body's immune function by stimu-
lating and enhancing specific anti-tumor immune re-
sponse in patients with various forms of cancer.15 Previ-
ous studies revealed that DCs regulated immune func-
tion in NSCLC patients through the balance of Th1/
Th2 cytokines.16 Ginseng polysaccharides are antitu-
mor agents isolated from Renshen (Radix Ginseng) that
act through immune regulation.17 Our findings demon-
strate that Th1 and Th2 cytokines and the ratio of
Th1/Th2 in the two groups were significantly changed
after treatment. Specifically Th1 cytokines and the ra-
tio of Th1/Th2 cytokines increased, while Th2 cyto-
kines decreased. The effect evident in the GPS plus
DCs group was greater than that of DCs alone. This
may be evidence of synergism between GPS and DCs
in regulating the immune function.
Based on the above findings, the positive effect of GPS
plus DCs on NSCLC patients' immune function was
greater than that of using DC alone. This suggests that
there is synergy between GPS and DCs when they
were administered together.
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